Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adalimumab in the treatment of immune-mediated diseases.
Lapadula G, Marchesoni A, Armuzzi A, Blandizzi C, Caporali R, Chimenti S, Cimaz R, Cimino L, Gionchetti P, Girolomoni G, Lionetti P, Marcellusi A, Mennini FS, Salvarani C. Lapadula G, et al. Among authors: gionchetti p. Int J Immunopathol Pharmacol. 2014 Jan-Mar;27(1 Suppl):33-48. doi: 10.1177/03946320140270S103. Int J Immunopathol Pharmacol. 2014. PMID: 24774505 Free article. Review.
Review article: the management of refractory Crohn's disease.
Rizzello F, Gionchetti P, Venturi A, Morselli C, Campieri M. Rizzello F, et al. Among authors: gionchetti p. Aliment Pharmacol Ther. 2002 Jul;16 Suppl 4:40-7. doi: 10.1046/j.1365-2036.16.s4.6.x. Aliment Pharmacol Ther. 2002. PMID: 12047259 Free article. Review.
Review article: medical treatment of severe ulcerative colitis.
Rizzello F, Gionchetti P, Venturi A, Campieri M. Rizzello F, et al. Among authors: gionchetti p. Aliment Pharmacol Ther. 2003 Jun;17 Suppl 2:7-10. doi: 10.1046/j.1365-2036.17.s2.18.x. Aliment Pharmacol Ther. 2003. PMID: 12786606 Free article. Review.
The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease.
Orlando A, Armuzzi A, Papi C, Annese V, Ardizzone S, Biancone L, Bortoli A, Castiglione F, D'Incà R, Gionchetti P, Kohn A, Poggioli G, Rizzello F, Vecchi M, Cottone M; Italian Society of Gastroenterology; Italian Group for the study of Inflammatory Bowel Disease. Orlando A, et al. Among authors: gionchetti p. Dig Liver Dis. 2011 Jan;43(1):1-20. doi: 10.1016/j.dld.2010.07.010. Epub 2010 Sep 16. Dig Liver Dis. 2011. PMID: 20843756
Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.
Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D'Inca R, Bossa F, Angelucci E, Biancone L, Gionchetti P, Ardizzone S, Papi C, Fries W, Danese S, Riegler G, Cappello M, Castiglione F, Annese V, Orlando A. Cottone M, et al. Among authors: gionchetti p. Clin Gastroenterol Hepatol. 2011 Jan;9(1):30-5. doi: 10.1016/j.cgh.2010.09.026. Epub 2010 Oct 15. Clin Gastroenterol Hepatol. 2011. PMID: 20951835
Adalimumab in active ulcerative colitis: a "real-life" observational study.
Italian Group for the Study of Inflammatory Bowel Disease; Armuzzi A, Biancone L, Daperno M, Coli A, Pugliese D, Annese V, Aratari A, Ardizzone S, Balestrieri P, Bossa F, Cappello M, Castiglione F, Cicala M, Danese S, D'Incà R, Dulbecco P, Feliciangeli G, Fries W, Genise S, Gionchetti P, Gozzi S, Kohn A, Lorenzetti R, Milla M, Onali S, Orlando A, Papparella LG, Renna S, Ricci C, Rizzello F, Sostegni R, Guidi L, Papi C. Italian Group for the Study of Inflammatory Bowel Disease, et al. Among authors: gionchetti p. Dig Liver Dis. 2013 Sep;45(9):738-43. doi: 10.1016/j.dld.2013.03.018. Epub 2013 May 15. Dig Liver Dis. 2013. PMID: 23683530 Free article.
The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases.
Blandizzi C, Gionchetti P, Armuzzi A, Caporali R, Chimenti S, Cimaz R, Cimino L, Lapadula G, Lionetti P, Marchesoni A, Marcellusi A, Mennini FS, Salvarani C, Girolomoni G. Blandizzi C, et al. Among authors: gionchetti p. Int J Immunopathol Pharmacol. 2014 Jan-Mar;27(1 Suppl):1-10. doi: 10.1177/03946320140270S101. Int J Immunopathol Pharmacol. 2014. PMID: 24774503 Free article. Review.
anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.
Armuzzi A, Lionetti P, Blandizzi C, Caporali R, Chimenti S, Cimino L, Gionchetti P, Girolomoni G, Lapadula G, Marchesoni A, Marcellusi A, Mennini FS, Salvarani C, Cimaz R. Armuzzi A, et al. Among authors: gionchetti p. Int J Immunopathol Pharmacol. 2014 Jan-Mar;27(1 Suppl):11-32. doi: 10.1177/03946320140270S102. Int J Immunopathol Pharmacol. 2014. PMID: 24774504 Free article. Review.
277 results